Literature DB >> 10503083

Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry.

E C Seaberg1, S H Belle, K C Beringer, J L Schivins, K M Detre.   

Abstract

CENTERS: Between 1988-1997, the total number of liver transplantations performed in the US more than doubled from 1,713-4,158, and the number of centers performing liver transplantations increased from 59-107. In recent years, the yearly net gain in the number of operating centers has slowed, and the differences in LT volume across centers has remained stable. OUTCOMES: During the first year following transplantation, patient survival was approximately the same for adults and children, while retransplantation-free survival was poorest among children. Thereafter, survival declined more rapidly among adults than among children. SURVIVAL AMONG PEDIATRIC RECIPIENTS: The estimated cumulative probability of a pediatric recipient surviving for 10 years following transplantation was .80, and surviving for 10 years without retransplantation was .59. In general, few deaths or retransplantations were observed more than 4 years after the initial transplantation. Factors independently associated with patient and retransplantation-free survival among children were year of transplantation, recipient age, being on life support while awaiting transplantation, primary liver disease, serum creatinine, total bilirubin, donor age, donor race, and warm ischemic time. Recipient race, a multi-organ transplant procedure, and serum albumin level were significantly associated with patient survival only. The use of a reduced-size or split liver for transplantation in children was independently associated with retransplantation-free survival, but not with patient survival. SURVIVAL AMONG ADULT RECIPIENTS: The estimated cumulative probability of an adult recipient surviving for 10 years following transplantation was .61, and surviving for 10 years without retransplantation was .46 with the median retransplantation-free survival time estimated at 9.2 years. Factors independently associated with patient and retransplantation-free survival among adults were year of transplantation, recipient age, recipient race, recipient location awaiting transplantation, primary liver disease, serum creatinine and albumin levels, hepatitis B surface antigen status, donor age, donor anti-CMV status, warm ischemic time, sex match, pretransplant ventilator or inotrope use, and recipient anti-HCV status. Pre-transplant bilirubin level, a multi-organ transplant procedure, and the finding of an incidental tumor were significantly associated with patient survival; and donor race, ABO match, and uncontrolled variceal bleeding were associated with retransplantation-free survival.

Entities:  

Mesh:

Year:  1998        PMID: 10503083

Source DB:  PubMed          Journal:  Clin Transpl        ISSN: 0890-9016


  29 in total

Review 1.  Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.

Authors:  Li Jiang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  Sirolimus therapy in orthotopic liver transplant (OLT) recipients with acute renal insufficiency.

Authors:  Marzia Montalbano; Guy W Neff; Grabriella Slapak-Green; Thierry Berney; Douglas Meyer
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 3.  Imaging in liver transplantation.

Authors:  Settimo Caruso; Roberto Miraglia; Luigi Maruzzelli; Salvatore Gruttadauria; Angelo Luca; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

4.  Long-term survival after liver transplantation in 4,000 consecutive patients at a single center.

Authors:  A Jain; J Reyes; R Kashyap; S F Dodson; A J Demetris; K Ruppert; K Abu-Elmagd; W Marsh; J Madariaga; G Mazariegos; D Geller; C A Bonham; T Gayowski; T Cacciarelli; P Fontes; T E Starzl; J J Fung
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

5.  Successful Lung Transplantation in a Patient with Chronic Granulomatous Disease.

Authors:  Maylene Xie; Janet Lee; Maria Crespo; Merritt L Fajt; Norihisa Shigemura; Joseph M Pilewski; Andrej A Petrov
Journal:  J Clin Immunol       Date:  2019-04-23       Impact factor: 8.317

6.  Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?

Authors:  Rosilene G Badiani; Vitória Becker; Renata M Perez; Carla A L Matos; Lara B Lemos; Valéria P Lanzoni; Luis Eduardo C Andrade; Alessandra Dellavance; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 7.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 8.  Treatment of hepatitis B and C following liver transplantation.

Authors:  Craig A Sponseller; Sanjay Ramrakhiani
Journal:  Curr Gastroenterol Rep       Date:  2002-02

9.  Liver transplantation.

Authors:  Deok-Bog Moon; Sung-Gyu Lee
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

10.  Liver transplantation in adults: Choosing the appropriate timing.

Authors:  Maria Siciliano; Lucia Parlati; Federica Maldarelli; Massimo Rossi; Stefano Ginanni Corradini
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.